To assess the efficacy of single-agent therapy relative to standard combination antibiotic therapy for the initial management of fever and neutropenia in cancer patients, we conducted a randomized trial comparing ceftazidime alone with a combination of cephalothin, gentamicin, and carbenicillin. Of 550 evaluable episodes of fever and neutropenia, 282 were treated with ceftazidime alone and 268 with the combination. All episodes were evaluated for responses at 72 hours after the start of treatment and at resolution of the neutropenia. Of the patients with unexplained fever who were given ceftazidime alone, 99 percent were alive at 72 hours and 98 percent were alive when the neutropenia resolved, as compared with 100 percent and 98 percent, respectively, of those given combination therapy. Of the patients with documented infection who were given ceftazidime alone, 98 percent were alive at 72 hours and 89 percent when the neutropenia resolved, as compared with 98 percent and 91 percent, respectively, of those given combination therapy. The majority of episodes of documented infection in both treatment groups necessitated additional antimicrobial treatment or other modifications of the initial regimen, as compared with only 22 percent of the episodes of unexplained fever. We conclude that initial single-agent therapy with certain beta-lactam antibiotics is a safe alternative to standard combination antibiotic therapy, although patients with documented infection or protracted neutropenia are likely to require additional or modified treatment.
This article has been cited by other articles:
Elting, L. S., Lu, C., Escalante, C. P., Giordano, S. H., Trent, J. C., Cooksley, C., Avritscher, E. B.C., Shih, Y.-C. T., Ensor, J., Bekele, B. N., Gralla, R. J., Talcott, J. A., Rolston, K.
(2008). Outcomes and Cost of Outpatient or Inpatient Management of 712 Patients With Febrile Neutropenia. JCO
26: 606-611
[Abstract][Full Text]
Paul, M., Borok, S., Fraser, A., Vidal, L., Leibovici, L.
(2005). Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother
55: 436-444
[Abstract][Full Text]
Niho, S., Ohe, Y., Goto, K., Ohmatsu, H., Matsumoto, T., Kubota, K., Kakinuma, R., Nishiwaki, Y.
(2004). Randomized Trial of Oral Versus Intravenous Antibiotics in Low-risk Febrile Neutropenic Patients with Lung Cancer. Jpn J Clin Oncol
34: 69-73
[Abstract][Full Text]
Paul, M., Soares-Weiser, K., Leibovici, L.
(2003). {beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ
326: 1111-
[Abstract][Full Text]
Stone, R. M.
(2002). The Difficult Problem of Acute Myeloid Leukemia in the Older Adult. CA Cancer J Clin
52: 363-371
[Abstract][Full Text]
Fleischhack, G., Hartmann, C., Simon, A., Wulff, B., Havers, W., Marklein, G., Hasan, C., Bode, U.
(2001). Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother
47: 841-853
[Abstract][Full Text]
Giamarellou, H., Bassaris, H. P., Petrikkos, G., Busch, W., Voulgarelis, M., Antoniadou, A., Grouzi, E., Zoumbos, N.
(2000). Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. Antimicrob. Agents Chemother.
44: 3264-3271
[Abstract][Full Text]
Feld, R., DePauw, B., Berman, S., Keating, A., Ho, W.
(2000). Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. JCO
18: 3690-3698
[Abstract][Full Text]
Chatzinikolaou, I., Abi-Said, D., Bodey, G. P., Rolston, K. V. I., Tarrand, J. J., Samonis, G.
(2000). Recent Experience With Pseudomonas aeruginosa Bacteremia in Patients With Cancer: Retrospective Analysis of 245 Episodes. Arch Intern Med
160: 501-509
[Abstract][Full Text]
Pizzo, P. A.
(1999). Fever in Immunocompromised Patients. NEJM
341: 893-900
[Full Text]
Freifeld, A., Marchigiani, D., Walsh, T., Chanock, S., Lewis, L., Hiemenz, J., Hiemenz, S., Hicks, J. E., Gill, V., Steinberg, S. M., Pizzo, P. A.
(1999). A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy. NEJM
341: 305-311
[Abstract][Full Text]
Finberg, R. W., Talcott, J. A.
(1999). Fever and Neutropenia -- How to Use a New Treatment Strategy. NEJM
341: 362-363
[Full Text]
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., Jarvis, W. R., The Glycopeptide-Intermediate Staphylococcus aureu,
(1999). Emergence of Vancomycin Resistance in Staphylococcus aureus. NEJM
340: 493-501
[Abstract][Full Text]
Tomlinson, R. J, Ronghe, M., Goodbourne, C., Price, C., Lilleyman, J. S, Das, S., Saha, V.
(1999). Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch. Dis. Child.
80: 125-131
[Abstract][Full Text]
Tod, M., Lortholary, O., Seytre, D., Semaoun, R., Uzzan, B., Guillevin, L., Casassus, P., Petitjean, O.
(1998). Population Pharmacokinetic Study of Amikacin Administered Once or Twice Daily to Febrile, Severely Neutropenic Adults. Antimicrob. Agents Chemother.
42: 849-856
[Abstract][Full Text]
Talcott, J. A.
(1997). Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?. The Oncologist
2: 365-373
[Abstract][Full Text]
Pizzo, P. A.
(1993). Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. NEJM
328: 1323-1332
[Full Text]
Wakeford, J. H., Hardin, T. C.
(1991). Sepsis. Journal of Pharmacy Practice
4: 269-280
Marchbanks, C. R., Rowley, K. A.
(1991). Update on Infections in the Immunocompromised Host. Journal of Pharmacy Practice
4: 282-294
[Abstract]
Previous
